Turning Point Therapeutics Quick Ratio (TPTX) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Turning Point Therapeutics Inc.  (NASDAQ: TPTX)

Turning Point Therapeutics's Quick Ratio

TPTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2022, Quick Ratio fell to 41.31 below Turning Point Therapeutics Inc. average.

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Quick Ratio than Turning Point Therapeutics in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 56 to 99.

Explain Quick Ratio?
How much Cash & cash equivalents TPTX´s has?
What are TPTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TPTX Quick Ratio (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2
Y / Y Current Liabilities Change 54.57 % 31.21 % -40.04 % 17.9 % 145.31 %
Y / Y Cash & cash equivalent Change -24.08 % -17.63 % -41.93 % 45.63 % 51.7 %
Quick Ratio MRQ 41.31 65.71 54.05 84.83 84.11
TPTX's Total Ranking # 99 # 56 # 72 # 33 # 44
Seq. Current Liabilities Change 41.76 % -23.05 % 48.69 % -4.7 % 20.34 %
Seq. Cash & cash equivalent Change -10.88 % -6.46 % -5.25 % -3.88 % -3.32 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 23
Overall Market # 99


Quick Ratio Statistics
High Average Low
136.01 68.67 25.66
(Jun 30 2020)   (Mar 31 2019)




Financial Statements
Turning Point Therapeutics's Current Liabilities $ 20 Millions Visit TPTX's Balance sheet
Turning Point Therapeutics's Cash & cash equivalent $ 818 Millions Visit TPTX's Balance sheet
Source of TPTX's Sales Visit TPTX's Sales by Geography


Cumulative Turning Point Therapeutics's Quick Ratio

TPTX's Quick Ratio for the trailling 12 Months

TPTX Quick Ratio

 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months
Y / Y Current Liabilities TTM Growth 0.07 % 1.14 % 6.62 % 50.2 % 55.78 %
Y / Y Cash & cash equivalent TTM Growth -18.29 % -5.05 % 20.53 % 122.38 % 138.76 %
Quick Ratio TTM 58.52 70.22 78.2 74.57 71.66
Total Ranking TTM # 4207 # 129 # 96 # 58 # 3345
Seq. Current Liabilities TTM Growth 12.23 % 6.17 % -18.38 % 2.89 % 13.43 %
Seq. Cash & cash equivalent TTM Growth -6.47 % -4.67 % -14.41 % 7.07 % 8.69 %

Quick ratio ranking by company, industry and sector >> Back to TPTX Financial Strength Comparisons >> Go to Compare TPTX Quick Ratio to its Competitors

On the trailing twelve months basis Due to jump in Current Liabilities in the Q2 2022 to $19.81 millions, cumulative Quick Ratio decreased to 58.52 above the TPTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 562 other companies have achieved higher Quick Ratio than Turning Point Therapeutics. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 129 to 4207.

Explain Quick Ratio?
How much Cash & cash equivalents TPTX´s has?
What are TPTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 563
Healthcare Sector # 1100
Within the Market # 4207


trailing twelve months Quick Ratio Statistics
High Average Low
43.4 33.31 20.76
(Mar 31 2021)   (Jun 30 2022)




Companies with similar Quick Ratio in the quarter ending Jun 30 2022, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2022 MRQ Cash & cash equivalentJun 30 2022 MRQ Current Liabilities
Cincor Pharma Inc   79.52 $ 294.312  Millions$ 3.701  Millions
Greenwich Lifesciences Inc   75.01 $ 17.188  Millions$ 0.229  Millions
Ars Pharmaceuticals Inc   71.82 $ 257.975  Millions$ 3.592  Millions
Altimmune inc   64.33 $ 184.756  Millions$ 2.872  Millions
Gh Research Plc  58.38 $ 265.377  Millions$ 4.546  Millions
Xenon Pharmaceuticals Inc   57.38 $ 788.238  Millions$ 13.736  Millions
Cohbar Inc   52.16 $ 20.097  Millions$ 0.385  Millions
Tyra Biosciences Inc   50.43 $ 275.107  Millions$ 5.455  Millions
Design Therapeutics Inc   48.64 $ 359.377  Millions$ 7.388  Millions
Tao Synergies Inc   45.93 $ 28.755  Millions$ 0.626  Millions
Lexaria Bioscience Corp   44.48 $ 7.339  Millions$ 0.165  Millions
Pasithea Therapeutics Corp   43.80 $ 47.940  Millions$ 1.094  Millions
Rezolute Inc   43.71 $ 150.410  Millions$ 3.441  Millions
Artelo Biosciences Inc   43.61 $ 22.981  Millions$ 0.527  Millions
Theseus Pharmaceuticals Inc   43.14 $ 224.795  Millions$ 5.211  Millions
Barinthus Biotherapeutics Plc  42.98 $ 192.327  Millions$ 4.475  Millions
Zomedica Corp   41.74 $ 186.763  Millions$ 4.474  Millions
Turning Point Therapeutics Inc.  41.31 $ 818.286  Millions$ 19.808  Millions
Aptinyx Inc   40.49 $ 85.269  Millions$ 2.106  Millions
Jade Biosciences Inc   40.47 $ 151.988  Millions$ 3.756  Millions
Annovis Bio Inc   39.89 $ 35.974  Millions$ 0.902  Millions
Prf Technologies Ltd   39.67 $ 19.954  Millions$ 0.503  Millions
Kezar Life Sciences Inc   39.07 $ 306.838  Millions$ 7.853  Millions
Savara Inc   38.43 $ 142.439  Millions$ 3.706  Millions
Enliven Therapeutics Inc   37.06 $ 122.363  Millions$ 3.302  Millions
Immuneering Corporation  36.45 $ 128.101  Millions$ 3.514  Millions
Nanoviricides inc   34.08 $ 14.070  Millions$ 0.413  Millions
Atossa Therapeutics Inc   33.13 $ 125.647  Millions$ 3.792  Millions
Nuvation Bio Inc   33.08 $ 703.797  Millions$ 21.274  Millions
Silo Pharma Inc  32.49 $ 8.734  Millions$ 0.269  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.